预约演示
更新于：2025-03-28
HB-0036
更新于：2025-03-28
概要
基本信息
原研机构 |
非在研机构- |
最高研发阶段临床1/2期 |
首次获批日期- |
最高研发阶段(中国)临床1/2期 |
特殊审评- |
登录后查看时间轴
关联
2
项与 HB-0036 相关的临床试验NCT05417321
A Phase I/II, Open-label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of HB0036 in Subjects With Advanced Solid Tumors
CTR20223172
一项评估 HB0036 治疗晚期实体肿瘤受试者的安全性、耐受性、药代动力学特征以及初步疗效的开放性、多中心 I/II 期临床研究
100 项与 HB-0036 相关的临床结果
登录后查看更多信息
100 项与 HB-0036 相关的转化医学
登录后查看更多信息
100 项与 HB-0036 相关的专利（医药）
登录后查看更多信息
2
项与 HB-0036 相关的文献（医药）1995-07-03Proceedings of the National Academy of Sciences of the United States of America1区 · 综合性期刊
Staphylococcal enterotoxins bind H-2Db molecules on macrophages.
1区 · 综合性期刊
Article
作者: Chapes, S K ; Beharka, A A ; Iandolo, J J
We screened a panel of monoclonal antibodies against selected macrophage cell surface molecules for their ability to inhibit enterotoxin binding to major histocompatibility complex class II-negative C2D (H-2b) macrophages. Two monoclonal antibodies, HB36 and TIB126, that are specific for the alpha 2 domain of major histocompatibility complex class I, blocked staphylococcal enterotoxins A and B (SEA and SEB, respectively) binding to C2D macrophages in a specific and concentration-dependent manner. Inhibitory activities were haplotype-specific in that SEA and SEB binding to H-2k or H-2d macrophages was not inhibited by either monoclonal antibody. HB36, but not TIB126, inhibited enterotoxin-induced secretion of cytokines by H-2b macrophages. Lastly, passive protection of D-galactosamine-sensitized C2D mice by injection with HB36 antibody prevented SEB-induced death. Therefore, SEA and SEB binding to the alpha 2 domain of the H-2Db molecule induces biological activity and has physiological consequences.
Global health research and policy
The effect of the capitation policy withdrawal on maternal health service provision in Ashanti Region, Ghana: an interrupted time series analysis
Article
作者: Mensah, Kofi Akohene ; Opoku, Daniel ; Atinga, Roger Ayimbillah ; Quentin, Wilm ; Yambah, John Kanyiri ; Laar, Kindness ; Ofori Boateng, Millicent ; Kuunibe, Naasegnibe
Abstract:
Background:
Payment methods are known to influence maternal care delivery in health systems. Ghana suspended a piloted capitation provider payment system after nearly five years of implementation. This study aimed to examine the effects of Ghana’s capitation policy on maternal health care provision as part of lesson learning and bridging this critical literature gap.
Methods:
We used secondary data in the District Health Information Management System-2 and an interrupted time series design to assess changes in level and trend in the provision of ANC4+ (visits of pregnant women making at least the fourth antenatal care attendance per month), HB36 (number of hemoglobin tests conducted for pregnant women who are at the 36th week of gestation) and vaginal delivery in capitated facilities-CHPS (Community-based Health Planning and Services) facilities and hospitals.
Results:
The results show that the capitation policy withdrawal was associated with a statistically significant trend increase in the provision of ANC4+ in hospitals (coefficient 70.99 p < 0. 001) but no effect in CHPS facilities. Also, the policy withdrawal resulted in contrasting effects in hospitals and CHPS in the trend of provision of Hb36; a statistically significant decline was observed in CHPS (coefficient − 7.01, p < 0.05) while that of hospitals showed a statistically significant trend increase (coefficient 32.87, p < 0.001). Finally, the policy withdrawal did not affect trends of vaginal delivery rates in both CHPS and hospitals.
Conclusions:
The capitation policy in Ghana appeared to have had a differential effect on the provision of maternal services in both CHPS and hospitals; repressing maternal care provision in hospitals and promoting adherence to anemia testing at term for pregnant women in CHPS facilities. Policy makers and stakeholders should consider the possible detrimental effects on maternal care provision and quality in the design and implementation of per capita primary care systems as they can potentially impact the achievement of SDG 3.
11
项与 HB-0036 相关的新闻（医药）2024-01-10
·米内网
一致性评价带量采购医药出海
2023-09-26
·药时代
临床1期免疫疗法临床终止引进/卖出临床结果
2023-07-25
抗体药物偶联物临床3期申请上市
100 项与 HB-0036 相关的药物交易
登录后查看更多信息
研发状态
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 晚期非小细胞肺癌 | 临床2期 | 美国 | 2022-08-25 | |
| 晚期非小细胞肺癌 | 临床2期 | 中国 | 2022-08-25 | |
| 局部晚期恶性实体瘤 | 临床2期 | 美国 | 2022-08-25 | |
| 局部晚期恶性实体瘤 | 临床2期 | 中国 | 2022-08-25 | |
| 食管鳞状细胞癌 | 临床1期 | 美国 | 2022-12-09 | |
| 食管鳞状细胞癌 | 临床1期 | 中国 | 2022-12-09 | |
| 胃食管交界处腺癌 | 临床1期 | 美国 | 2022-12-09 | |
| 胃食管交界处腺癌 | 临床1期 | 中国 | 2022-12-09 | |
| 肝细胞癌 | 临床1期 | 美国 | 2022-12-09 | |
| 肝细胞癌 | 临床1期 | 中国 | 2022-12-09 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1/2期 | 19 | 鏇網網選窪壓襯範繭淵(鏇鏇餘襯簾膚積鹽廠範) = ≥10% 憲齋壓遞膚醖醖願窪構 (構醖襯齋窪壓遞壓積衊 ) 更多 | 积极 | 2024-05-24 | |||
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
生物类似药
生物类似药在不同国家/地区的竞争态势。请注意临床1/2期并入临床2期，临床2/3期并入临床3期
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用